NCT03793166 2026-05-29Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyNational Cancer Institute (NCI)Phase 3 Active not recruiting1,175 enrolled